https://doi.org/10.55788/b7e00352
The phase 3 BOREAS trial (NCT03930732) randomised 939 patients with moderate to severe COPD with type 2 inflammation 1:1 to dupilumab or placebo [1]. The primary outcome was the annualised rate of moderate to severe exacerbations from baseline to week 52. Prof. Klaus Rabe (LungenClinic Grosshansdorf GmbH, Germany) presented the primary results of the trial, which were simultaneously published in the New England Journal of Medicine [2].
Although almost all patients were on triple therapy, dupilumab reduced the annualised exacerbation rate by 30% compared with placebo (0.78 vs 1.10; P<0.001). Prof. Rabe showed that this result was consistent across subgroups. Notably, at week 12 the change from baseline least squares means pre-bronchodilator forced expiratory volume in 1 second (FEV1) was 83 ml larger in the experimental group than in the placebo group (P<0.001), and this difference remained stable up to week 52. Similarly, patient-reported outcome measures displayed swift improvements after dupilumab therapy was initiated and these improvements stabilised over time.
In conclusion, on top of triple therapy, dupilumab was able to reduce the exacerbation rates in patients with COPD with type 2 inflammation in a large phase 3 trial.
- Bhatt SP, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. B13, ATS International Conference 2023, 19–24 May, Washington DC, USA.
- Bhatt SP, et al. NEJM. 2023; May 21. DOI: 10.1056/NEJMoa2303951.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« New AATD therapy may alleviate treatment burden for patients Next Article
Alvelestat for AATD meets primary endpoints in phase 2 trial »
« New AATD therapy may alleviate treatment burden for patients Next Article
Alvelestat for AATD meets primary endpoints in phase 2 trial »
Table of Contents: ATS 2023
Featured articles
TORREY trial: seralutinib associated with reduced pulmonary vascular resistance in PAH
Practice-changing results for ensifentrine in COPD
Asthma
Vitamin D for asthma protection: what is the optimal timing?
Remarkable results for novel biologic therapy for asthma
Success for fluticasone furoate plus vilanterol in uncontrolled asthma
COPD
Practice-changing results for ensifentrine in COPD
Alvelestat for AATD meets primary endpoints in phase 2 trial
Fewer exacerbations with dupilumab in COPD with type 2 inflammation
New AATD therapy may alleviate treatment burden for patients
Efficient detection of AECOPD with at-home vital signs monitoring
COVID-19
COVA trial: success for the investigational agent sarconeos in hospitalised COVID-19
Mitochondrial DNA levels predict COVID-19 severity
Other
Excellent results for C21 in idiopathic pulmonary fibrosis
Can camlipixant improve quality of life of patients with refractory chronic cough?
TORREY trial: seralutinib associated with reduced pulmonary vascular resistance in PAH
Improving quality care in sepsis through machine learning models
Can information technology improve guideline adherence in sepsis care?
Related Articles
October 30, 2022
Antifibrotic therapy may slow down FVC decline in RAILD
August 17, 2022
Lung cancer screening in Denmark
September 5, 2020
For refractory obstructive sleep apnea, surgery may be effective
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy